UAB Leads International Study

Sep 14, 2022 at 07:32 am by steve

UAB researchers are leading an international study to see whether a blood-clotting agent, given soon after arrival in the emergency department, can improve survival.

The Center for Injury Science, in the UAB Marnix E. Heersink School of Medicine, was awarded $5,507,307 by CSL Behring to help conduct the study, which is one of the largest clinical trials ever conducted in the field of trauma.

The trial will determine whether prothrombin complex concentrate, also known as Kcentra®, reduces mortality in trauma patients who will require large volume blood transfusions. PCC contains multiple blood-clotting factors and is currently approved for use as a therapy for hemophilia and to reverse the effects of anticoagulant medications, such as warfarin. If shown to be effective, treatment with PCC could transform the standard of care for bleeding trauma patients and save thousands of lives.

The trial's principal investigator is Jan Jansen, MBBS, PhD, director of CIS. John Holcomb, MD is the co-principal investigator and Shannon Stephens, CCEMTPis the program manager.

The trial will be conducted in about 140 leading trauma centers in several countries and will include 8,000 patients, making it the second-largest trauma trial ever conducted.

Sections: Grand Rounds